Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 13/20 | 0.45 |
| ▸ | JAK2 | O60674 | 11/20 | 0.45 |
| ▸ | TYK2 | P29597 | 4/20 | 0.45 |
| ▸ | JAK3 | P52333 | 4/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21757052 | 0.91 | JAK1 (0.43) | JAK1JAK2TYK2JAK3ALDH1A1 | |
| SCHEMBL21756990 | 0.89 | JAK1 (0.42) | JAK1JAK2TYK2JAK3ALDH1A1 | |
| SCHEMBL19159529 | 0.86 | JAK3 (0.47) | JAK1JAK2TYK2JAK3OPRM1 | |
| SCHEMBL22007006 | 0.85 | JAK1 (0.49) | JAK1JAK2TYK2JAK3OPRM1 | |
| SCHEMBL23584408 | 0.81 | HSD11B1 (0.50) | JAK1JAK2TYK2JAK3OPRM1 | |
| SCHEMBL6421780 | 0.77 | ALDH1A1 (0.58) | JAK2JAK3ALDH1A1NPC1KDM4E | |
| SCHEMBL21757037 | 0.77 | JAK2 (0.45) | JAK1JAK2TYK2OPRM1OPRL1 | |
| SCHEMBL21757030 | 0.76 | OPRM1 (0.43) | OPRM1OPRL1ALDH1A1MEN1KMT2A | |
| SCHEMBL17177171 | 0.76 | KDM4E (0.41) | JAK1JAK2TYK2JAK3OPRM1 | |
| SCHEMBL22754610 | 0.76 | JAK1 (0.43) | JAK1JAK2TYK2JAK3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4105214-A1 | USE OF JAK INHIBITORS IN PREPARATION OF DRUGS FOR TREATING JAK KINASE-RELATED DISEASES | Zhuhai United Laboratories Co., Ltd (CN) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022161205-A1 | ORAL PREPARATION CONTAINING JAK INHIBITOR OR SALT THEREOF OR CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 珠海联邦制药股份有限公司 | 2022-08-04 | — | — | WO | disclosed |
| WO-2021159372-A1 | USE OF JAK INHIBITORS IN PREPARATION OF DRUGS FOR TREATING JAK KINASE-RELATED DISEASES | 珠海联邦制药股份有限公司 | 2021-08-19 | — | — | WO | disclosed |
| EP-3842431-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUND AS JAK INHIBITOR AND APPLICATION THEREOF | Zhuhai United Laboratories Co., Ltd (CN) | 2021-06-30 | — | — | EP | disclosed |
| US-20210155621-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUND AS JAK INHIBITOR AND USE THEREOF | ZHUHAI UNITED LABORATORIES CO., LTD. (CN) | 2021-05-27 | — | — | US | disclosed |
| WO-2020038457-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUND AS JAK INHIBITOR AND APPLICATION THEREOF | 珠海联邦制药股份有限公司 | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155621-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUND AS JAK INHIBITOR AND USE THEREOF | JAK1, JAK2, TYK2 | JAK1 1/4885JAK2 2/4885TYK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.